[1] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon.
[2] DeSantis, C., Ma, J., Bryan, L. and Jemal, A, (2014) Breast Cancer Statistics, 2013. CA Caner Journal for Clinicians, 64, 52-62.
https://doi.org/10.3322/caac.21203
[3] DeSantis, C., Siegel, R., Bandi, P. and Jemal, A. (2011) Breast Cancer Statistics, 2011. CA Caner Journal for Clinicians, 61, 409-418.
https://doi.org/10.3322/caac.20134
[4] National Cancer Institute (2014) Cancer of the Breast—SEER Stat Fact Sheets [Internet]. Surveillance, Epidemiology, and End Results Program.
http://seer.cancer.gov/statfacts/html/breast.html
[5] Smigal, C., Jemal, A., Ward, E., Cokkinides, V., Smith, R., Howe, H.L., et al. (2006) Trends in Breast Cancer by Race and Ethnicity: Update 2006. CA: A Cancer Journal for Clinicians, 56, 168-183.
https://doi.org/10.3322/canjclin.56.3.168
[6] Ashing-Giwa, K.T., Padilla, G., Tejero, J., Kraemer, J., Wright, K., Coscarelli, A., et al. (2004) Understanding the Breast Cancer Experience of Women: A Qualitative Study of African American, Asian American, Latina and Caucasian Cancer Survivors. Psycho-Oncology, 13, 408-428.
https://doi.org/10.1002/pon.750
[7] Clegg, L.X., Reichman, M.E., Miller, B.A., Hankey, B.F., Singh, G.K., Lin, Y.D., et al. (2009) Impact of Socioeconomic Status on Cancer Incidence and Stage at Diagnosis: Selected Findings from the Surveillance, Epidemiology, and End Results: National Longitudinal Mortality Study. Cancer Causes Control, 20, 417-435.
https://doi.org/10.1007/s10552-008-9256-0
[8] Wei, L.J. (1992) The Accelerated Failure Time Model: A Useful Alternative to the Cox Regression Model in Survival Analysis. Statistics in Medicine, 11, 1871-1879.
https://doi.org/10.1002/sim.4780111409
[9] Strasser-Weippl, K. and Goss, P.E. (2013) Competing Risks in Low-Risk Breast Cancer. American Society of Clinical Oncology Educational Book, 32-39.
https://doi.org/10.1200/EdBook_AM.2013.33.32
[10] Rosenberg, M.A. (2006) Competing Risks to Breast Cancer Mortality. JNCI Monographs, 36, 15-19.
https://doi.org/10.1093/jncimonographs/lgj004
[11] Lin, D.Y. (1997) Non-Parametric Inference for Cumulative Incidence Functions in Competing Risks Studies. Statistics in Medicine, 16, 901-910.
https://doi.org/10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M
[12] Dignam, J.J., Zhang, Q. and Kocherginsky, M. (2012) The Use and Interpretation of Competing Risks Regression Models. Clinical Cancer Research, 18, 2301-2308.
https://doi.org/10.1158/1078-0432.CCR-11-2097
[13] McGiffin, D.C., Naftel, D.C., Kirklin, J.K., Morrow, W.R., Towbin, J., Shaddy, R., et al. (1997) Predicting Outcome after Listing for Heart Transplantation in Children: Comparison of Kaplan-Meier and Parametric Competing Risk Analysis. The Journal of Heart and Lung Transplantation, 16, 713-722.
[14] National Cancer Institute (2015) Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. www.seer.cancer.gov
[15] National Cancer Institute (NCI) (2016) Surveillance, Epidemiology, and End Results Program.
http://seer.cancer.gov.
[16] Noone, A.M., Lund, J.L., Mariotto, A., Cronin, K., McNeel, T., Deapen, D. and Warren, J.L. (2016) Comparison of SEER Treatment Data with Medicare Claims. Medical Care, 54, e55-e64.
https://doi.org/10.1097/mlr.0000000000000073
[17] Warren, J.L., Harlan, L.C., Fahey, A., Virnig, B.A., Freeman, J.L., Klabunde, C.N., et al. (2002) Utility of the SEER-Medicare Data to Identify Chemotherapy Use. Medical Care, 40, IV-55-IV-61.
https://doi.org/10.1097/00005650-200208001-00008
[18] Prentice, R.L., Kalbfleisch, J.D., Peterson Jr., A.V., Flournoy, N., Farewell, V.T. and Breslow, N.E. (1978) The Analysis of Failure Times in the Presence of Competing Risks. Biometrics, 34, 541-554.
https://doi.org/10.2307/2530374
[19] Kalbfleisch, J.D. and Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. Wiley, New York.
[20] Maller, R.A. and Zhou, X. (2002) Analysis of Parametric Models for Competing Risks. Statistica Sinica, 12, 725-750.
[21] Jogi, A., Vaapil, M., Johansson, M. and Pahlman, S. (2012) Cancer Cell Differentiation Heterogeneity and Aggressive Behavior in Solid Tumors. Upsala Journal of Medical Sciences, 117, 217-224.
https://doi.org/10.3109/03009734.2012.659294
[22] Keegan, T.H., DeRouen, M.C., Press, D.J., Kurian, A.W. and Clarke, C.A. (2012) Occurrence of Breast Cancer Subtypes in Adolescent and Young Adult Women. Breast Cancer Research, 14, R55.
https://doi.org/10.1186/bcr3156
[23] Colzani, E., Liljegren, A., Johansson, A.L., Adolfsson, J., Hellborg, H., Hall, P.F. and Czene, K. (2011) Prognosis of Patients with Breast Cancer: Causes of Death and Effects of Time since Diagnosis, Age, and Tumor Characteristics. Journal of Clinical Oncology, 29, 4014-4021.
https://doi.org/10.1200/JCO.2010.32.6462
[24] Alison, P.D. Macro Smooth. Statistical Horizons 2010.
http://www.statisticalhorizons.com/resources/macros
[25] Beaver, K., Luker, K.A., Owens, R.G., Leinster, S.J., Degner, L.F. and Sloan, J.A. (1996) Treatment Decision Making in Women Newly Diagnosed with Breast Cancer. Cancer Nursing, 19, 8-19.
https://doi.org/10.1097/00002820-199602000-00002
[26] Kantorová, I., Lipská, L., Bêlohlávek, O., Visokai, V., Trubac, M. and Schneiderová, M. (2003) Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making. Journal of Nuclear Medicine, 44, 1784-1788.
[27] Valanis, B.G. and Rumpler, C.H. (1985) Helping Women to Choose Breast Cancer Treatment Alternatives. Cancer Nursing, 8, 167-176.
https://doi.org/10.1097/00002820-198506000-00005
[28] Shumay, D.M., Maskarinec, G., Kakai, H. and Gotay, C.C. (2001) Why Some Cancer Patients Choose Complementary and Alternative Medicine Instead of Conventional Treatment. Journal of Family Practice, 50, 1067.
[29] Campbell, J.D. and Ramsey, S.D. (2009) The Costs of Treating Breast Cancer in the US. Pharmacoeconomics, 27, 199-209.
https://doi.org/10.2165/00019053-200927030-00003
[30] Clark, R.M., McCulloch, P.B., Levine, M.N., Lipa, M., Wilkinson, R.H., Mahoney, L. J., Corbett, P.J., et al. (1992) Randomized Clinical Trial to Assess the Effectiveness of Breast Irradiation Following Lumpectomy and Axillary Disection for Node-Negative Breast Cancer. Journal of the National Cancer Institute, 84, 683-689.
https://doi.org/10.1093/jnci/84.9.683
[31] Whelan, T.J., Julian, J., Wright, J., Jadad, A.R. and Levine, M.L. (2000) Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis. Journal of Clinical Oncology, 18, 1220-1229.
[32] Steward, L.T., Gao, F., Taylor, M.A. and Margenthaler, J.A. (2014) Impact of Radiation Therapy on Survival in Patients with Triple-Negative Breast Cancer. Oncology Letters, 7, 548-552.